Francesca Giusti1, Luisella Cianferotti1, Francesca Boaretto2, Filomena Cetani3, Federica Cioppi1, Annamaria Colao4, Maria Vittoria Davì5, Antongiulio Faggiano6, Giuseppe Fanciulli7, Piero Ferolla8, Diego Ferone9, Caterina Fossi1, Francesco Giudici1, Giorgio Gronchi1, Paola Loli10, Franco Mantero11, Claudio Marcocci3, Francesca Marini1, Laura Masi1, Giuseppe Opocher2, Paolo Beck-Peccoz12, Luca Persani13,14, Alfredo Scillitani15, Giovanna Sciortino13,14, Anna Spada16, Paola Tomassetti17, Francesco Tonelli1, Maria Luisa Brandi18. 1. Department of Surgery and Translational Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy. 2. Familial Tumor Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. 3. Department of Clinical and Experimental Medicine, Section of Endocrinology, University of Pisa, Pisa, Italy. 4. Endocrinology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. 5. Internal Medicine, Section of Endocrinology, Department of Medicine, University of Verona, Verona, Italy. 6. Thyroid and Parathyroid Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale" IRCCS, Naples, Italy. 7. NET Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 8. Department of Internal Medicine and Endocrine Sciences, University of Perugia, Perugia, Italy. 9. Endocrinology Units, Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy. 10. Department of Endocrinology, Hospital Niguarda Ca' Granda, Milan, Italy. 11. Division of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy. 12. Professor Emeritus of the University of Milan, Milan, Italy. 13. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 14. Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy. 15. Unit of Endocrinology 'Casa Sollievo della Sofferenza' Hospital, IRCCS, San Giovanni Rotondo, Foggia, Italy. 16. Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. 17. Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Bologna, Italy. 18. Department of Surgery and Translational Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy. marialuisa.brandi@unifi.it.
Abstract
OBJECTIVE: The aim of this study was to integrate European epidemiological data on patients with multiple endocrine neoplasia type 1 by creating an Italian registry of this syndrome, including clinical and genetic characteristics and therapeutic management. METHODS: Clinical, familial and genetic data of patients with multiple endocrine neoplasia type 1, diagnosed, treated, and followed-up for a mean time of 11.3 years, in 14 Italian referral endocrinological centers, were collected, over a 3-year course (2011-2013), to build a national electronic database. RESULTS: The Italian multiple endocrine neoplasia type 1 database includes 475 patients (271 women and 204 men), of whom 383 patients (80.6%) were classified as familial cases (from 136 different pedigrees), and 92 (19.4%) patients were sporadic cases. A MEN1 mutation was identified in 92.6% of familial cases and in 48.9% of sporadic cases. Four hundred thirty-six patients were symptomatic, presenting primary hyperparathyroidism, gastroenteropancreatic neuroendocrine tumors and pituitary tumors in 93, 53, and 41% of cases, respectively. Thirty-nine subjects, belonging to affected pedigrees positive for a MEN1 mutation, were asymptomatic at clinical and biochemical screening. Age at diagnosis of multiple endocrine neoplasia type 1 probands was similar for both familial and simplex cases (mean age 47.2 ± 15.3 years). In familial cases, diagnosis of multiple endocrine neoplasia type 1 in relatives of affected probands was made more than 10 years in advance (mean age at diagnosis 36.5 ± 17.6 years). CONCLUSIONS: The analysis of Italian registry of multiple endocrine neoplasia type 1 patients revealed that clinical features of Italian multiple endocrine neoplasia type 1 patients are similar to those of other western countries, and confirmed that the genetic test allowed multiple endocrine neoplasia type 1 diagnosis 10 years earlier than biochemical or clinical diagnosis.
OBJECTIVE: The aim of this study was to integrate European epidemiological data on patients with multiple endocrine neoplasia type 1 by creating an Italian registry of this syndrome, including clinical and genetic characteristics and therapeutic management. METHODS: Clinical, familial and genetic data of patients with multiple endocrine neoplasia type 1, diagnosed, treated, and followed-up for a mean time of 11.3 years, in 14 Italian referral endocrinological centers, were collected, over a 3-year course (2011-2013), to build a national electronic database. RESULTS: The Italian multiple endocrine neoplasia type 1 database includes 475 patients (271 women and 204 men), of whom 383 patients (80.6%) were classified as familial cases (from 136 different pedigrees), and 92 (19.4%) patients were sporadic cases. A MEN1 mutation was identified in 92.6% of familial cases and in 48.9% of sporadic cases. Four hundred thirty-six patients were symptomatic, presenting primary hyperparathyroidism, gastroenteropancreatic neuroendocrine tumors and pituitary tumors in 93, 53, and 41% of cases, respectively. Thirty-nine subjects, belonging to affected pedigrees positive for a MEN1 mutation, were asymptomatic at clinical and biochemical screening. Age at diagnosis of multiple endocrine neoplasia type 1 probands was similar for both familial and simplex cases (mean age 47.2 ± 15.3 years). In familial cases, diagnosis of multiple endocrine neoplasia type 1 in relatives of affected probands was made more than 10 years in advance (mean age at diagnosis 36.5 ± 17.6 years). CONCLUSIONS: The analysis of Italian registry of multiple endocrine neoplasia type 1 patients revealed that clinical features of Italian multiple endocrine neoplasia type 1 patients are similar to those of other western countries, and confirmed that the genetic test allowed multiple endocrine neoplasia type 1 diagnosis 10 years earlier than biochemical or clinical diagnosis.
Authors: Jeffrey A Norton; Douglas L Fraker; H R Alexander; Fathia Gibril; David J Liewehr; David J Venzon; Robert T Jensen Journal: Ann Surg Date: 2006-09 Impact factor: 12.969
Authors: J Thevenon; A Bourredjem; L Faivre; C Cardot-Bauters; A Calender; M Le Bras; S Giraud; P Niccoli; M F Odou; F Borson-Chazot; A Barlier; C Lombard-Bohas; E Clauser; A Tabarin; E Pasmant; O Chabre; E Castermans; P Ruszniewski; J Bertherat; B Delemer; S Christin-Maitre; A Beckers; I Guilhem; V Rohmer; B Goichot; P Caron; E Baudin; P Chanson; L Groussin; H Du Boullay; G Weryha; P Lecomte; F Schillo; H Bihan; F Archambeaud; V Kerlan; N Bourcigaux; J M Kuhn; B Vergès; M Rodier; M Renard; J L Sadoul; C Binquet; P Goudet Journal: Eur J Endocrinol Date: 2015-09-21 Impact factor: 6.664
Authors: M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Joanne M de Laat; Olaf M Dekkers; Carolina R C Pieterman; Wouter P Kluijfhout; Ad R Hermus; Alberto M Pereira; Anouk N van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Wouter W de Herder; Gerlof D Valk Journal: J Clin Endocrinol Metab Date: 2015-06-30 Impact factor: 5.958
Authors: B Gatta-Cherifi; O Chabre; A Murat; P Niccoli; C Cardot-Bauters; V Rohmer; J Young; B Delemer; H Du Boullay; M F Verger; J M Kuhn; J L Sadoul; Ph Ruszniewski; A Beckers; M Monsaingeon; E Baudin; P Goudet; A Tabarin Journal: Eur J Endocrinol Date: 2011-11-14 Impact factor: 6.664
Authors: Maria A Kouvaraki; Jeffrey E Lee; Suzanne E Shapiro; Robert F Gagel; Steven I Sherman; Rena V Sellin; Gilbert J Cote; Douglas B Evans Journal: Arch Surg Date: 2002-06
Authors: Terry C Lairmore; Linda D Piersall; Mary K DeBenedetti; William G Dilley; Matthew G Mutch; Alison J Whelan; Barbara Zehnbauer Journal: Ann Surg Date: 2004-05 Impact factor: 12.969
Authors: Jens Waldmann; Volker Fendrich; Nils Habbe; Detlef K Bartsch; Emily P Slater; Peter H Kann; Matthias Rothmund; Peter Langer Journal: World J Surg Date: 2009-06 Impact factor: 3.352
Authors: Julien Thevenon; Abderrahmane Bourredjem; Laurence Faivre; Catherine Cardot-Bauters; Alain Calender; Arnaud Murat; Sophie Giraud; Patricia Niccoli; Marie-Françoise Odou; Françoise Borson-Chazot; Anne Barlier; Catherine Lombard-Bohas; Eric Clauser; Antoine Tabarin; Béatrice Parfait; Olivier Chabre; Emilie Castermans; Albert Beckers; Philippe Ruszniewski; Morgane Le Bras; Brigitte Delemer; Philippe Bouchard; Isabelle Guilhem; Vincent Rohmer; Bernard Goichot; Philippe Caron; Eric Baudin; Philippe Chanson; Lionel Groussin; Hélène Du Boullay; Georges Weryha; Pierre Lecomte; Alfred Penfornis; Hélène Bihan; Françoise Archambeaud; Véronique Kerlan; Françoise Duron; Jean-Marc Kuhn; Bruno Vergès; Michel Rodier; Michel Renard; Jean-Louis Sadoul; Christine Binquet; Pierre Goudet Journal: Hum Mol Genet Date: 2013-01-31 Impact factor: 6.150
Authors: R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano Journal: J Endocrinol Invest Date: 2022-08-30 Impact factor: 5.467
Authors: Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker Journal: Endocr Rev Date: 2021-03-15 Impact factor: 19.871